ArticleClinical and translational science2025
Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Multifaceted Role of Extracellular Vesicles in Triple Negative Breast Cancer.International journal of molecular sciences · 2026Review
- Small extracellular vesicles in tumor metabolism and immune escape: biomarkers and therapeutic opportunities.Molecular biology reports · 2026Review
- Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with limited targeted therapeutic options. Exosomes, small membrane vesicles secreted by cells, play a crucial role in intercellular communication and material exchange. However, the role of exosome-related genes (ERGs) in TNBC remains unclear. In here, we analyzed single-cell RNA sequencing (scRNA-seq) from 10 TNBC samples and bulk RNA-seq from TCGA and METABRIC cohorts. Starting with 121 EDPS curated from the breast cancer-specific ExoBCD database, we identified exosome-active cell populations and derived an Exosome-Derived Prognostic Signature (EDPS) through integrative machine learning. Our analysis identified 31,140 cells from TNBC samples, categorized into nine cell types, with epithelial cells exhibiting the highest exosome-related scores. A total of 232 differentially expressed genes (DEGs) related to exosome-related scores were identified, with 19 prognostic genes selected through univariate Cox regression, leading to the construction of an EDPS. Low EDPS scores correlated with poorer clinical outcomes, higher immune infiltrates, and immune-related pathways. Furthermore, we identified notable differences in biological functions and mutation profiles between the two EDPS groups. Additionally, the low EDPS score group exhibited lower tumor immune dysfunction and exclusion (TIDE) scores, immunophenoscore (IPS), and higher immune checkpoint expression, suggesting better immunotherapy outcomes. In conclusion, while derived from exosome-related genes, the EDPS primarily reflects immune-active tumor microenvironments. This signature may help identify TNBC patients likely to benefit from immunotherapy, though further validation of its relationship to exosome biology is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.